Resources

Trial in Progress: A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)with H3K27M alteration
> View

BXQ-350 for the Treatment of Solid Tumors: Modulating Ceramides and Sphingosine-1-Phosphate
> View

BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation of apoptotic caspases in vitro.
> View

First-in-human, First-in-Class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas
> View

First-in-human, First-in-class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas.
> View

---

Absence of Indicators of Hypercoagulability and Anti-phospholipid Syndrome in BXQ-350 First in Human Study.
> View

---

Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles.
> View

Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial

Conflict of Interest Statement: Dr. Rixe holds a minor (<0.01%) equity interest in Bexion Pharmaceuticals, Inc.

On Tuesday, June 22, 2021, Dr. Ray Takigiku, Founder and CEO of Bexion, participated in AngelMD’s Pitch Club, “Innovations in Oncology”.